Caris Life Sciences, Inc. reports results for the quarter ended September 30 - Earnings Summary
Caris Life Sciences, Inc. reported quarterly adjusted earnings of 5 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 8 cents. The mean expectation of thirteen analysts for the quarter was for earnings of 3 cents per share. Wall Street expected results to range from -1 cents to 8 cents per share.
Revenue rose 27% to $275.36 million from a year ago; analysts expected $255.36 million.
Caris Life Sciences, Inc.'s reported EPS for the quarter was 5 cents.
The company reported quarterly net income of $15.25 million.
Caris Life Sciences, Inc. shares had risen by 7.2% this quarter and gained 21.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 22.9% in the last three months.
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for Caris Life Sciences, Inc. is $30.00, about 9.5% below its last closing price of $32.85
This summary was machine generated from LSEG data November 4 at 10:47 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2026 | 0.03 | 0.05 | Beat |
Jun. 30 2026 | 0.01 | 0.00 | Missed |
Mar. 31 2026 | -0.02 | 0.00 | Beat |
Dec. 31 2025 | 0.03 | 0.28 | Beat |